Zimmer Biomet Holdings, Inc. (ZBH) stock analysis
Healthcare · Medical Devices
From the 10-K filed 2026-02-20
Business type: Franchise
How it makes money
It generates 85% of revenue through consignment sales, where the company retains title to implants until the surgical procedure occurs.
Profitability is driven by large-joint reconstructive hardware, specifically the Persona Knee and Taperloc Hip systems. These products are often sold as part of the ZBEdge Platform, which integrates hardware with ROSA robotic technology to assist surgeons with implant positioning.
End users are orthopedic surgeons and hospitals, but the company primarily bills healthcare institutions only after a device is used. The United States is the dominant market, accounting for 95% of sales within the Americas segment.
What protects it: the moat
The company maintains over 6,000 issued patents and relies on a specialized sales force to provide technical support for complex surgical procedures.
Management claims that the technical expertise of its sales associates, who must provide real-time support to surgeons, creates a barrier to entry. This is reinforced by the consignment model, which keeps the company's inventory physically staged in hospital facilities, increasing switching costs for institutions.
The ZBEdge Platform further protects earnings by creating a digital ecosystem that leverages data analytics and artificial intelligence, making its implants more integral to the hospital's workflow.
What growth costs
The company recognized $181.2 million in restructuring expenses in 2025 while executing a multi-year initiative to convert its sales force to direct employees.
Maintaining market position requires substantial reinvestment in research and development, which employed 2,000 people at the end of 2025. Beyond internal R&D, it aggressively acquires growth through deals like Paragon 28, which added 2.5% to net sales but required inventory step-up costs.
The business is also structurally required to fund high levels of inventory and specialized instruments to support its 85% consignment sales model, leading to recent inventory charges of $170 million for discontinued lines.
What could damage it
Transitioning the United States sales force to employee status risks the loss of high-performing distributors and their critical customer relationships to competitors.
A permanent impairment could occur if independent agents, who hold long-term professional relationships with surgeons, decline employment with it. These departures can lead to immediate sales coverage gaps and the loss of entire accounts to rivals.
Additionally, the business faces significant risk from product obsolescence; it recently identified $170 million in inventory and instrument charges related to product lines it intends to discontinue by 2032.
About Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.